BEVERLY, MA – April 19, 2017 (GLOBE NEWSWIRE) Cellceutix Corporation (OTCQB: CTIX), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory and antibiotic applications, provides additional details for upcoming shareholder and investor presentations.
On the morning of April 20, 2017, at 11AM Eastern (EST), a pre-recorded presentation, audio and corresponding slide deck, will be made available at the Events and Presentation section of the company’s website, linked to below:
The presentation will include a brief corporate update from Leo Ehrlich, Chief Executive Officer, and a clinical overview by Dr. Arthur Bertolino, MD, PHD, MBA, President and Chief Medical Officer, with particular emphasis given to Brilacidin interim trial results in Inflammatory Bowel Disease and Oral Mucositis.
Additionally, the Company is fielding shareholder and investor questions in advance of a live conference call, scheduled for June 8, 2017 at 11AM EST, as follow-up to the next quarterly report (10-Q) to be released in May. Questions for the June call may be submitted in advance by emailing firstname.lastname@example.org and must be received by June 1, 2017 at 5pm EST. Dial-in instructions for participants will be announced one week prior.
Sign-up for Cellceutix email alerts at: http://www.cellceutix.com/email-alerts